Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Fig. 4

Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix. To test the ability of leronlimab to block cell invasion in 3D Matrigel invasion assay, MDA-MB-231 cells were used. CCL5 was used as chemoattractant to induce invasion. The small-molecule inhibitor of CCR5, vicriviroc, was used as a form of positive control. Leronlimab reduced CCL5-induced MDA-MB-231 breast cancer cell invasion with similar efficacy as vicriviroc (a, b) (855 ± 8.7, N = 8 for control vs. 520 ± 9.1, N = 9 for leronlimab, P < 0.001). We also tested the effects of leronlimab doses on breast cancer cell invasion, and the results showed that both 175 and 350 μg/ml of leronlimab can effectively block MDA-MB-231 cell invasion (c, d)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us